Article Text
Statistics from Altmetric.com
Q Are routine rotavirus vaccinations (3 times/infant) cost effective in the US?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Paediatrics (general) ★★★★★★☆ Public health ★★★★★★☆
METHODS
Design:
cost effectiveness study using a probabilistic (Monte Carlo) model.
Setting:
nationwide in the US.
Patients:
a hypothetical cohort of 4 010 000 children monitored from 0 to 59 months of age.
Intervention:
routine vaccinations for infants at 2, 4, and 6 months of age with a pentavalent human bovine reassortant rotavirus vaccine (PVR) (RotaTeq; Merck, Whitehouse Station, NJ, USA) or no vaccinations.
Outcomes:
deaths, hospital admissions, emergency department visits, office visits, and episodes with home care; and the cost effectiveness ratio per case (any disease) averted, per serious case (hospital admission, …
Footnotes
-
For correspondence: Dr M A Widdowson, Centers for Disease Control and Prevention, Atlanta, GA, USA. mwiddowson{at}cdc.gov
-
Source of funding: Centers for Disease Control and Prevention.